|
|
|
|
|
|
Brain Met Survival by Therapy (from the literature)
|
|
|
|
|
|
Brain Met Survival by Therapy (from the literature)
|
IJROBP 1999;43:795 |
| The survival of patients with brain metastases depends on multiple factors. Patients with cancer only in the brain and in good physical shape may benefit from brain surgery followed by radiation and live months or even years. Patients with cancer spread to multiple other parts of the body and in poor shape may have such a short survival (weeks to a few months) that no therapy may be beneficial. One of the most important predictors of survival is the patient's performance score (KPS or Karnofsky score or ECOG score) which is a measure of how active the patient is (patients who are ambulatory have a high performance score and those in a coma would have a very low performance score.) Another good predictor of survival is the RTOG classification as defined below. Some general survival statistics are as noted: |
| Therapy | Survival |
| Steroids Only | 1.3 months |
| Radiation | 3.6 months |
| Surgery + Radiation | 8.9 months |
| Class | Characteristics | Median Survival |
| I | KPS>70, primary controlled, age <65y, mets to brain only | 7.1 - 10.5 months |
| II | KPS >70 | 3.5 - 4.2 months |
| III | KPS < 70 | 2.0 - 2.3 months |
| PS (ECOG) | Median Survival | Survival at 1 years |
| 0 | 7.8 months | 32% |
| 1 | 4.5 months | 15% |
| 2 | 2.3 months | 7% |
| 3 | 1.4 months | 3% |
